Aleix Prat, Director of the Clínic Barcelona Comprehensive Cancer Center at Barcelona Clinical Hospital, shared a poat on LinkedIn about a paper he co-authored with colleagues published in Clinical Cancer Research:
“New study published: encouraging results for a novel treatment strategy in advanced HER2+ breast cancer
I’m pleased to share that our recent work, ‘Palbociclib, trastuzumab and endocrine therapy in pretreated HER2-positive and PAM50-luminal advanced breast cancer: randomised phase II, SOLTI-1303 PATRICIA trial’, has just been published in hashtag Clinical Cancer Research – AACR Journals.
In this randomized Phase II trial, we evaluated the efficacy of combining palbociclib + trastuzumab + endocrine therapy versus standard-of-care trastuzumab-based treatment in previously treated patients with HER2-positive, HR-positive, PAM50-Luminal A/B advanced breast cancer.
Key findings:
- The triplet regimen was associated with a significantly longer progression-free survival (PFS): hazard ratio 0.52 (95 % CI 0.29–0.95), p = 0.03. PubMed
- After 24 months, PFS rate was 24.0 % with the triplet vs 4.3 % with standard care.
- Safety profile was acceptable: although grade ≥ 3 adverse events were relatively frequent (notably neutropenia), no permanent discontinuations due to toxicity were observed.
These results suggest that combining palbociclib, trastuzumab and endocrine therapy could represent a promising strategy to improve outcomes in this specific subset of advanced breast cancer patients.
Thank you to all collaborators and patients who made this study possible.”
Title: Palbociclib, trastuzumab and endocrine therapy in pretreated HER2-positive and PAM50 luminal advanced breast cancer: randomised phase II, SOLTI-1303 PATRICIA trial
Authors: Eva Ciruelos, Tomás Pascual, Guillermo Villacampa, Sonia Pernas, Rodrigo Sanchez Bayona, José Ponce, Blanca Cantos, Santiago Escrivá-de-Romaní, Antonia Perelló, Esther Sanfeliu, Patricia Galvan, Alvaro Montaño, Eduardo Martínez, Ana Lopez, Mireia Mele, Juan de la Haba, Javier Cortés, Antonio Mulero-Sánchez, Juan M. Ferrero-Cafiero, Mafalda Oliveira, Lorea Villanueva, Xavier Gonzalez, Patricia Villagrasa, Aleix Prat
You can read the full article in Clinical Cancer Research.
More posts about Breast Cancer on OncoDaily.